Table 3.
DOTATATE- and PSMA-Related Radiopeptides Delivered via IA in Clinical Trials.
| Study Name [Reference Number] | Radiopharmaceutical Used | Phase | # of Participants |
|---|---|---|---|
| Intra-arterial Lutetium-177-dotatate for Treatment of Patients with Neuro-endocrine Tumor Liver Metastases (LUTIA) [NCT03590119] | Lu-177-DOTATATE | 2/3 | 26 |
| Lutathera in People with Gastroenteropancreatic (GEP), Bronchial, or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver [NCT04544098] | Lu-177-DOTATATE | 1 | 10 |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabeled Somatostatin Analogs in GEP-NET Patients with Dominant Liver Metastases (LUTARTERIAL) [NCT04837885] | Lu-177-DOTATATE | 2 | 20 |
| Personalized PRRT of Neuroendocrine Tumors (P-PRRT) [NCT02754297] | Lu-177-Octreotate | 2 | 300 |
| Comparison of Hepatic Intra-arterial vs. Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma [NCT05111314] | Ga-68-Gozetotide | 1 | 10 |
| Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion [NCT04976257] | Ga-68-PSMA-11 | 1 | 5 |